Literature DB >> 12111606

Clinical impact of nosocomial Klebsiella bacteremia in critically ill patients.

S I Blot1, K H Vandewoude, F A Colardyn.   

Abstract

In order to determine the clinical impact of Klebsiella bacteremia on critically ill patients, a matched cohort study was conducted between January 1992 and December 2000. During the study period, all intensive care unit (ICU) patients with nosocomial Klebsiella bacteremia were defined as cases (n=52), but two of these patients were excluded from the matched cohort due to incomplete medical records. The remaining 50 patients were matched at a ratio of 1:2 with control patients (n=100) on the basis of the APACHE II severity of disease classification system. Patients with Klebsiella bacteremia experienced acute renal failure and hemodynamic instability more often than controls. They also had a longer ICU stay and longer ventilator dependence. In-hospital mortality rates for cases and controls were nearly equal (36% vs. 37%, respectively; P=0.905). In conclusion, after adjusting accurately for severity of underlying disease and acute illness, no difference in mortality was found between ICU patients with Klebsiella bacteremia and their matched control subjects.

Entities:  

Mesh:

Year:  2002        PMID: 12111606     DOI: 10.1007/s10096-002-0746-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  Acute Klebsiella pneumoniae pneumonia alone and with concurrent infection: comparison of clinical and thin-section CT findings.

Authors:  F Okada; Y Ando; K Honda; T Nakayama; A Ono; S Tanoue; T Maeda; H Mori
Journal:  Br J Radiol       Date:  2010-07-20       Impact factor: 3.039

2.  Invasive devices: no need? No use!

Authors:  Stijn I Blot; Renaat Peleman; Koenraad H Vandewoude
Journal:  Intensive Care Med       Date:  2006-12-05       Impact factor: 17.440

3.  Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study.

Authors:  Stijn Blot; Koenraad Vandewoude; Francis Colardyn
Journal:  Intensive Care Med       Date:  2003-02-08       Impact factor: 17.440

4.  Factors associated with antimicrobial resistance among clinical isolates of Klebsiella pneumoniae: 1-year survey in a French university hospital.

Authors:  C De Champs; C Rich; P Chandezon; C Chanal; D Sirot; C Forestier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-18       Impact factor: 3.267

5.  Clinical and pulmonary thin-section CT findings in acute Klebsiella pneumoniae pneumonia.

Authors:  Fumito Okada; Yumiko Ando; Koichi Honda; Tomoko Nakayama; Maki Kiyonaga; Asami Ono; Shuichi Tanoue; Toru Maeda; Hiromu Mori
Journal:  Eur Radiol       Date:  2008-11-26       Impact factor: 5.315

6.  Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality.

Authors:  John R Prowle; Jorge E Echeverri; E Valentina Ligabo; Norelle Sherry; Gopal C Taori; Timothy M Crozier; Graeme K Hart; Tony M Korman; Barrie C Mayall; Paul D R Johnson; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-03-21       Impact factor: 9.097

7.  Comparison of severity of illness scoring systems for patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa.

Authors:  Alexandre R Marra; Gonzalo M L Bearman; Richard P Wenzel; Michael B Edmond
Journal:  BMC Infect Dis       Date:  2006-08-17       Impact factor: 3.090

8.  Community-acquired versus nosocomial Klebsiella pneumonia bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance.

Authors:  Dominique M Vandijck; Johan M Decruyenaere; Pieter O Depuydt; Stijn I Blot
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153

9.  Intensive care unit-acquired bacteremia in mechanically ventilated patients: clinical features and outcomes.

Authors:  Hsin-Kuo Ko; Wen-Kuang Yu; Te-Cheng Lien; Jia-Horng Wang; Arthur S Slutsky; Haibo Zhang; Yu Ru Kou
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.